These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 21269258)

  • 21. Natural compounds with proteasome inhibitory activity for cancer prevention and treatment.
    Yang H; Landis-Piwowar KR; Chen D; Milacic V; Dou QP
    Curr Protein Pept Sci; 2008 Jun; 9(3):227-39. PubMed ID: 18537678
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
    Gatti L; Benedetti V; De Cesare M; Corna E; Cincinelli R; Zaffaroni N; Zunino F; Perego P
    J Inorg Biochem; 2012 Aug; 113():94-101. PubMed ID: 22717676
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The potential of proteasome inhibitors in cancer therapy.
    Sterz J; von Metzler I; Hahne JC; Lamottke B; Rademacher J; Heider U; Terpos E; Sezer O
    Expert Opin Investig Drugs; 2008 Jun; 17(6):879-95. PubMed ID: 18491989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting the proteasome pathway.
    Tsukamoto S; Yokosawa H
    Expert Opin Ther Targets; 2009 May; 13(5):605-21. PubMed ID: 19397479
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacology, pharmacokinetics, and practical applications of bortezomib.
    Schwartz R; Davidson T
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):14-21. PubMed ID: 15688598
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery, Development, and clinical applications of bortezomib.
    Jung L; Holle L; Dalton WS
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):4-13. PubMed ID: 15688597
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bortezomib for previously untreated multiple myeloma.
    Delforge M
    Expert Opin Pharmacother; 2011 Nov; 12(16):2553-64. PubMed ID: 21942881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bortezomib: a proteasome inhibitor with an evolving role in select subtypes of B-cell non-Hodgkin's lymphoma.
    Koprivnikar JL; Cheson BD
    Future Oncol; 2012 Apr; 8(4):359-71. PubMed ID: 22515439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proteasome inhibition as a novel therapeutic target in human cancer.
    Rajkumar SV; Richardson PG; Hideshima T; Anderson KC
    J Clin Oncol; 2005 Jan; 23(3):630-9. PubMed ID: 15659509
    [TBL] [Abstract][Full Text] [Related]  

  • 30. "Development of the proteasome inhibitor Velcade (Bortezomib)" by Julian Adams, Ph.D., and Michael Kauffman, M.D., Ph.D.
    Bold R
    Cancer Invest; 2004; 22(2):328-9. PubMed ID: 15199617
    [No Abstract]   [Full Text] [Related]  

  • 31. Bortezomib inhibits cell-cell adhesion and cell migration and enhances epidermal growth factor receptor inhibitor-induced cell death in squamous cell cancer.
    Lorch JH; Thomas TO; Schmoll HJ
    Cancer Res; 2007 Jan; 67(2):727-34. PubMed ID: 17234784
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.
    Bladé J; Cibeira MT; Rosiñol L
    Acta Oncol; 2005; 44(5):440-8. PubMed ID: 16118077
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of bortezomib in the treatment of lymphoma.
    Barr P; Fisher R; Friedberg J
    Cancer Invest; 2007 Dec; 25(8):766-75. PubMed ID: 18058474
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proteasome inhibitor attenuates skeletal muscle reperfusion injury by blocking the pathway of nuclear factor-kappaB activation.
    Park JW; Qi WN; Cai Y; Urbaniak JR; Chen LE
    Plast Reconstr Surg; 2007 Dec; 120(7):1808-1818. PubMed ID: 18090742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of proteasome in malignant diseases.
    Moran E; Nencioni A
    J BUON; 2007 Sep; 12 Suppl 1():S95-9. PubMed ID: 17935285
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The potential role of bortezomib in combination with chemotherapy and radiation in non-small-cell lung cancer.
    Edelman MJ
    Clin Lung Cancer; 2005 Oct; 7 Suppl 2():S64-6. PubMed ID: 16250930
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
    Ludwig H; Khayat D; Giaccone G; Facon T
    Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The ubiquitin-proteasome system (UPS) and the mechanism of action of bortezomib.
    Cvek B; Dvorak Z
    Curr Pharm Des; 2011; 17(15):1483-99. PubMed ID: 21504411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Macrocyclic proteasome inhibitors.
    Krahn D; Ottmann C; Kaiser M
    Curr Med Chem; 2011; 18(33):5052-60. PubMed ID: 22050753
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proteasome inhibitors in pediatric cancer treatment.
    Bachmann AS
    Hawaii Med J; 2008 Sep; 67(9):247-9. PubMed ID: 18853901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.